Physician * Oncology - Hematology/Oncology Follow

Evan Lipson, MD


EvanLipsonMD (Verified)

Communities:
Melanoma (Cutaneous)
Answers: 
8


Joined
Feb. 2012
Emailz

Professional Statement

Dr. Lipson received his Bachelor of Arts in economics from the University of Maryland in 1996. After working as a producer at CNN's "Larry King Live" for a few years, he completed a post-baccalaureate program at Georgetown University in Washington, DC. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at the Johns Hopkins Hospital, and completed his Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center.

Dr. Lipson's primary research interest is in early phase clinical trials for melanoma and other cutaneous malignancies. As a member of the Johns Hopkins Melanoma Program and the Immunology Program at the Kimmel Cancer Center, he focuses on evaluating novel therapies for patients with high risk or advanced disease. Dr. Lipson is a co-investigator on multiple trials, involving partners from both industry and academia, which address two major areas of opportunity in melanoma therapeutics: immunotherapy and molecular pathway inhibition. With an eye toward developing synergistic combinatorial therapies, Dr. Lipson is leading clinical research to test a cellular melanoma vaccine – melanoma GVAX – designed to stimulate T-cell immunity in melanoma patients. Other immunomodulatory therapies under investigation, including monoclonal antibodies such as anti-PD-1 and anti-B7-H1, have shown early promise in clinical trials led by Johns Hopkins investigators and may eventually be combined with vaccine therapies. Dr. Lipson and his colleagues recently authored a book chapter reviewing the state-of-the-art on these therapies.

In related research, Dr. Lipson is collaborating with Hopkins' expert Dr. Jim Herman to evaluate the impact of gene silencing (epigenetics) on immunoregulatory and anti-angiogenesis pathways in melanoma. These studies aim to better identify early stage melanoma patients who are at risk for disease progression, and to select those patients with advanced disease who are most likely to respond to immune-based therapy.

In addition to his research activities, Dr. Lipson conducts a regular clinical practice as part of the multidisciplinary Melanoma Program at Johns Hopkins. To learn more or schedule an appointment, call 410-616-7660.

Dr. Lipson is also the founder of “Seize the Days,” a non-profit organization that chronicles the stories of cancer patients who, with power and determination, find interesting and meaningful ways to add life to their days. For more information, visit http://seizethedays.org.
Give a 'Thank you' to
Thought for
Close
TalkAboutHealth
Please join TalkAboutHealth and you will be able to ask questions.
Join Now
Close
Your question to EvanLipsonMD:
2) Background Info (optional): What context or background information is relevant to this request?
Notes:
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
Close
Talk About Health
Please join TalkAboutHealth and you will be able to ask questions.
Newsletters
Close
Subscribe to our free updates for the latest news, best answers and featured experts!
Your Email:
Q&A Workshop Announcements
(Featured experts, answers, tips, & latest news.)
Q&A Workshop Summaries
(Answer summaries from our expert Q&A workshops.)
Best of TalkAboutHealth (weekly)
(The week's best answers, news & support.)
TalkAboutHealth Benefits
(Custom health, wellness & medical promotions from our partners.)
New Message
To (username):
Subject:
Message:

Partners become a partner

© Copyright 2014 - Talk About Health - Privacy Policy | Terms of Service
x Don't show again
Like us on Facebook?